Evidence map›Paper›PMID 42852299›Full record

ArticleACS omega2026

Design, Synthesis, and Microbiological Evaluation of Differently Decorated Pyrazoles Able to Overcome Antimicrobial Resistance and Biofilm Formation.

Matteo Lusardi, Debora Caviglia, Andrea Chiocca, Marco Ponassi, Gabriella Piatti, Annalisa Salis, Andrea Spallarossa, Anna M Schito, Chiara Brullo

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Matteo LusardiDepartment of Pharmacy (DIFAR), Section of Medicinal Chemistry, University of Genoa, Viale Benedetto XV, 3, 16132 Genova, Italy.ORCID https://orcid.org/0000-0002-7003-7891
Debora CavigliaDepartment of Pharmacy (DIFAR), Section of Medicinal Chemistry, University of Genoa, Viale Benedetto XV, 3, 16132 Genova, Italy.
Andrea ChioccaDepartment of Pharmacy (DIFAR), Section of Medicinal Chemistry, University of Genoa, Viale Benedetto XV, 3, 16132 Genova, Italy.
Marco PonassiAzienda Ospedaliera Metropolitana Genova, UOS Proteomica e Spettrometria di Massa, L.go. R. Benzi, 10, 16132 Genova, Italy.
Gabriella PiattiDepartment of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Viale Benedetto XV, 6, 16132 Genova, Italy.
Annalisa SalisDepartment of Experimental Medicines (DIMES), University of Genoa, Largo Rosanna Benzi 10, PAD.3, 16132 Genova, Italy.
Andrea SpallarossaDepartment of Pharmacy (DIFAR), Section of Medicinal Chemistry, University of Genoa, Viale Benedetto XV, 3, 16132 Genova, Italy.
Anna M SchitoDepartment of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Viale Benedetto XV, 6, 16132 Genova, Italy.
Chiara BrulloDepartment of Pharmacy (DIFAR), Section of Medicinal Chemistry, University of Genoa, Viale Benedetto XV, 3, 16132 Genova, Italy.ORCID https://orcid.org/0000-0002-2575-7726

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance is an urgent global public health threat, killing at least 1.27 million people worldwide and associated with nearly 5 million deaths. Antibiotic resistance has been recently recognized by the WHO as a global health emergency. In this scenario, the research and development of novel derivatives specifically active against resistant pathogens became an urgent need. Pyrazole-based compounds have recently attracted significant interest for their potential antimicrobial activity, particularly against resistant Gram-positive strains such as methicillin-resistant

Identifiers

PMID42852299
PMCPMC13647960

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.